MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/hem3.29

Медицинская библиотека · HemaSphere · 2024

High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma.

O'Reilly Maeve A, Neill Lorna, Collin Simon M, Stone Neil, Springell Deborah, Mensah Jeremy, Cheok Kathleen P L, Jalowiec Katarzyna, Benjamin Reuben, Kuhnl Andrea, Roddie Claire, Sanderson Robin

СтатьяПеревод в очереди

Аннотация

Infection has emerged as the chief cause of non-relapse mortality (NRM) post CD19-targeting chimeric antigen receptor T-cell therapy (CAR-T) therapy. Even though up to 50% of patients may remain infection-free, many suffer multiple severe, life-threatening, or fatal infectious events. The primary aim of this study was to explore severe and life-threatening infections post licensed CAR-T therapy in large B-cell lymphoma, with a focus on the role of disease burden and disease sites in assessing individual risk. We sought to understand the cohort of patients who experience ≥2 infections and those at the highest risk of infectious NRM. Our analysis identifies a higher disease burden after bridging therapy as associated with infection events. Those developing ≥2 infections emerged as a uniquely high-risk cohort, particularly if the second (or beyond) infection occurred during an episode of immune effector cell-associated neurotoxicity syndrome (ICANS) or while on steroids and/or anakinra for ICANS. Herein, we also describe the first reported cases of "CAR-T cold sepsis," a phenomenon characterized by the lack of an appreciable systemic inflammatory response at the time of detection of infection. We propose a risk-based strategy to encourage heightened clinician awareness of cold sepsis, with a view to reducing NRM.

Для цитирования: O'Reilly Maeve A, Neill Lorna, Collin Simon M, Stone Neil, Springell Deborah, Mensah Jeremy, Cheok Kathleen P L, Jalowiec Katarzyna, Benjamin Reuben, Kuhnl Andrea, Roddie Claire, Sanderson Robin. High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma.. HemaSphere. 2024. DOI: 10.1002/hem3.29.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.